Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 2/20 | 0.89 |
| ▸ | APP | P05067 | 9/20 | 0.84 |
| ▸ | MAPT | P10636 | 6/20 | 0.84 |
| ▸ | BACE1 | P56817 | 3/20 | 0.84 |
| ▸ | MAOB | P27338 | 3/20 | 0.84 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.84 |
| ▸ | MMP9 | P14780 | 3/20 | 0.84 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.84 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.84 |
| ▸ | TSHR | P16473 | 2/20 | 0.84 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.84 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.84 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.84 |
| ▸ | MAOA | P21397 | 2/20 | 0.84 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.84 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.84 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.84 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.84 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.84 |
| ▸ | STAT3 | P40763 | 2/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27686673 | 1.00 | TOP2A (0.89) | TOP2AAPPMAPTBACE1MAOB | |
| Water SCHEMBL28118110 | 0.99 | TOP2A (0.87) | TOP2AAPPMAPTBACE1MAOB | |
| Ethyl Curcumin SCHEMBL8965263 | 0.94 | TOP2A (1.00) | TOP2AAPPMAPTBACE1MAOB | |
| Ethyl Curcumin SCHEMBL8965258 | 0.94 | TOP2A (1.00) | TOP2AAPPMAPTBACE1MAOB | |
| Curcumin SCHEMBL2804734 | 0.92 | APP (1.00) | TOP2AAPPMAPTBACE1MAOB | |
| Curcumin SCHEMBL17629819 | 0.92 | APP (1.00) | TOP2AAPPMAPTBACE1MAOB | |
| Curcumin SCHEMBL8440 | 0.92 | APP (1.00) | TOP2AAPPMAPTBACE1MAOB | |
| Curcumin SCHEMBL250984 | 0.92 | APP (1.00) | TOP2AAPPMAPTBACE1MAOB | |
| Curcumin SCHEMBL17629818 | 0.92 | APP (1.00) | TOP2AAPPMAPTBACE1MAOB | |
| Curcumin SCHEMBL6901740 | 0.92 | APP (1.00) | TOP2AAPPMAPTBACE1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180852-A1 | TREATMENT FOR MALIGNANT PLEURAL EFFUSION IN HUMANS | SIGNPATH PHARMA, INC. | 2024-06-06 | — | — | US | claimed |
| EP-4301469-A1 | TREATMENT FOR MALIGNANT PLEURAL EFFUSION IN HUMANS | Signpath Pharma, Inc. (US) | 2024-01-10 | — | — | EP | claimed |
| EP-4188398-A1 | SUPPRESSION OF CYTOKINE RELEASE AND CYTOKINE STORM | Signpath Pharma, Inc. (US) | 2023-06-07 | — | — | EP | claimed |
| WO-2022187351-A1 | TREATMENT FOR MALIGNANT PLEURAL EFFUSION IN HUMANS | SIGNPATH PHARMA, INC (US) | 2022-09-09 | — | — | WO | claimed |
| WO-2022026170-A1 | SUPPRESSION OF CYTOKINE RELEASE AND CYTOKINE STORM | SIGNPATH PHARMA, INC. (US) | 2022-02-03 | — | — | WO | claimed |
| US-20200360300-A1 | Suppression of Cytokine Release and Cytokine Storm | SIGNPATH PHARMA, INC. | 2020-11-19 | — | — | US | claimed |
| US-10739353-B2 | Suppression of cytokine release and cytokine storm | SIGNPATH PHARMA, INC. (US) | 2020-08-11 | — | — | US | claimed |
| US-20190105287-A1 | Liposomal Curcumin for Treatment of Cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-04-11 | — | — | US | claimed |
| US-20180318217-A1 | Liposomal Curcumin for Treatment of Diseases | SIGNPATH PHARMA INC. | 2018-11-08 | — | — | US | claimed |
| US-10004687-B2 | Liposomal curcumin for treatment of diseases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-06-26 | — | — | US | claimed |
| US-20100316631-A1 | Water Soluble Curcumin-Based Compounds | THE UAB RESEARCH FOUNDATION (US) | 2010-12-16 | — | — | US | claimed |
| US-20080138400-A1 | Curcumin analog or metabolite microencapsulated by a polyethylene glycolated liposome of dimyristoyl phosphatidylcholine, cholesterol, and dimyristoyl phsphatidylethanolamine; anticarcinogenic and antiproliferative agents; parenteral colloidal drug delivery system providing improved bioavailability | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-06-12 | — | — | US | claimed |
| WO-2008051474-A1 | WATER SOLUBLE CURCUMIN-BASED COMPOUNDS | THE UAB RESEARCH FOUNDATION (US) | 2008-05-02 | — | — | WO | claimed |
| US-20080103213-A1 | LIPOSOMAL CURCUMIN FOR TREATMENT OF NEUROFIBROMATOSIS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-05-01 | — | — | US | claimed |
| EP-1887869-A2 | COMPOSITION AND METHOD FOR THE TREATMENT OF ALLERGIC RHINITIS | Ram, A.N. Sunder (US) | 2008-02-20 | — | — | EP | claimed |
| US-20080031980-A1 | Curcumin-containing composition, methods of making, and methods of using | FARR LABORATORIES, LLC | 2008-02-07 | — | — | US | claimed |
| US-20060275516-A1 | Compositions and methods for the treatment of allergic rhinitis | RAM A N S | 2006-12-07 | — | — | US | claimed |
| WO-2006130679-A2 | COMPOSITION AND METHOD FOR THE TREATMENT OF ALLERGIC RHINITIS | RAM A N SUNDER (US) | 2006-12-07 | — | — | WO | claimed |
| US-20060067998-A1 | Curcumin analog or metabolite microencapsulated by a polyethylene glycolated liposome of dimyristoyl phosphatidylcholine, cholesterol, and dimyristoyl phsphatidylethanolamine; parenteral colloidal drug delivery system providing improved bioavailability | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2006-03-30 | — | — | US | claimed |
| WO-2004080396-A2 | LIPOSOMAL CURCUMIN FOR TREATMENT OF CANCER | THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER (US) | 2004-09-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060067998-A1 | Curcumin analog or metabolite microencapsulated by a polyethylene glycolated liposome of dimyristoyl phosphatidylcholine, cholesterol, and dimyristoyl phsphatidylethanolamine; parenteral colloidal drug delivery system providing improved bioavailability | PNLIP, SGMS2, SGMS1 | TOP2A 4186/4885APP 904/4885MAPT 850/4885 |
| US-20190105287-A1 | Liposomal Curcumin for Treatment of Cancer | PNLIP, BRCA1, IAPP | TOP2A 2414/4885APP 2489/4885MAPT 1839/4885 |
| US-20240180852-A1 | TREATMENT FOR MALIGNANT PLEURAL EFFUSION IN HUMANS | MTDH, PLEC, LPCAT3 | TOP2A 2958/4885APP 3737/4885MAPT 3156/4885 |
| US-20200360300-A1 | Suppression of Cytokine Release and Cytokine Storm | TNF, IL6, IL1B | TOP2A 3566/4885APP 366/4885MAPT 1287/4885 |
| US-20180318217-A1 | Liposomal Curcumin for Treatment of Diseases | LIPA, LPCAT3, LCLAT1 | TOP2A 2075/4885APP 1019/4885MAPT 1067/4885 |
| US-20080138400-A1 | Curcumin analog or metabolite microencapsulated by a polyethylene glycolated liposome of dimyristoyl phosphatidylcholine, cholesterol, and dimyristoyl phsphatidylethanolamine; anticarcinogenic and antiproliferative agents; parenteral colloidal drug delivery system providing improved bioavailability | LCAT, SGMS2, SGMS1 | TOP2A 2112/4885APP 1631/4885MAPT 1252/4885 |
| US-10739353-B2 | Suppression of cytokine release and cytokine storm | TNF, IL2, IL6 | TOP2A 3671/4885APP 369/4885MAPT 1425/4885 |
| US-10004687-B2 | Liposomal curcumin for treatment of diseases | LIPA, LPCAT3, LCLAT1 | TOP2A 2075/4885APP 1019/4885MAPT 1067/4885 |
| US-20080103213-A1 | LIPOSOMAL CURCUMIN FOR TREATMENT OF NEUROFIBROMATOSIS | MEN1, VHL, CALM1 | TOP2A 3888/4885APP 168/4885MAPT 1677/4885 |
| US-20060275516-A1 | Compositions and methods for the treatment of allergic rhinitis | HRH2, HRH4, HRH3 | TOP2A 4730/4885APP 1906/4885MAPT 2260/4885 |
| US-20100316631-A1 | Water Soluble Curcumin-Based Compounds | BAD, TP53, CD14 | TOP2A 3335/4885APP 2374/4885MAPT 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.